Research programme: zinc finger DNA-binding protein nucleases - Sangamo Therapeutics
Alternative Names: SB-LSD3; SB-LSD4; ZFN Bcl11a; ZFN therapeutics - Sangamo; ZFP nucleases - SangamoLatest Information Update: 31 Mar 2022
At a glance
- Originator Sangamo BioSciences
- Developer Sangamo Therapeutics; University of Massachusetts Medical School
- Class Antineoplastics; Cell therapies; Gene therapies; Stem cell therapies; Zinc finger DNA binding proteins
- Mechanism of Action Alpha 1-antitrypsin modulators; CCR5 receptor modulators; Cell replacements; Gene modulators; Gene silencing; Genetic transcription inhibitors; Interleukin 2 receptor modulators; T-cell receptor gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alpha 1-antitrypsin deficiency; Cancer; Down syndrome; HIV infections; Immunodeficiency disorders; Mucopolysaccharidosis I; Mucopolysaccharidosis II
Most Recent Events
- 22 Feb 2022 Sangamo Therapeutics has multiple patents protection for zinc finger DNA-binding protein nucleases in USA
- 07 Feb 2018 Case Western Reserve University and Sangamo Therapeutics plans a phase I trial for HIV infections in USA in 2018
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alpha-1-antitrypsin-deficiency in USA (Parenteral)